Introduction to Translational Medicine
10 May 2018, 6:30 – 7:30pm
SingHealth Academia, 20 College Road, L1-S1
Translational medicine can be defined as the continuum from a scientific idea or finding to a diagnostic tool and/or therapy applied to human diseases. The field of translational medicine encompasses molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among other disciplines. Translational Medicine has emerged as a discipline central to the goal of converting basic science discoveries to diagnostic and therapeutic tools that can be harnessed to treat disease and improve human health.
What are the key factors influencing the evolution of a scientific discovery or concept through the translational gradient to answer an unmet medical need. A lot of science is outstanding, but not all of it is “druggable”.
- Highlight the principles guiding movement from initial investigations into “advanced” studies
- Discuss designing and managing clinical trials, including data management and interpretation
- Explore the intersection of interests between key stakeholders
|6:15 pm||Registration starts||–|
|6:30 – 6:35 pm||Welcome Address||Professor Salvatore Albani, Director of Translational Immunology Institute (TII) & President of Eureka Institute|
|6:35 – 6:40 pm||Welcome address||Dr. Chin Sau Yau, President, Biotech Connection Singapore|
|6:40 – 7.00 pm||Introduction to Translational Medicine (TM) – Principles of TM and Is your technology marketable?||Professor Salvatore Albani|
|7:00 – 7.30 pm||Panel Discussion and Audience Q&A||Professor Salvatore Albani
Mr. XiangLiang Lin, Founder and CEO of Vaccixcell, Director of Market Development for Esco Group
(Check back for full list)
|7:30 pm||Refreshments and Networking||–|
Professor Salvatore Albani, Professor at Duke-NUS Graduate Medical School Singapore, Director of the SingHealth Translational Immunology & Inflammation Centre, and Senior Clinical Scientist with the Paediatrics Academic Clinical Program. Professor Albani is an internationally renowned rheumatologist and immunologist. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to conclusion of Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. This translational research itinerary has been the original backbone of his career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc) and by approximately 100 patents, disclosures and applications.
Mr. XiangLiang Lin